EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

The Nasdaq 100 has suffered its worst quarter in nearly three years, slumping 8.3% amid growing fears of an artificial intelligence (AI) bubble. Already pressured by tariff uncertainties, government spending cuts, and recession threats, the tech-heavy index witnessed fresh selling after warnings about a potential slowdown in AI-driven infrastructure investment.AI Stocks Bear the BruntTech giants that once led the market’s rally have taken significant hits. NVIDIA Corp. (NVDA) has plunged 28% from its Januar ...

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman and CEO Greg Duncan stated, “We appreciate the consideration Nasdaq has shown Dogwood Therapeutics, Inc.” He continu ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy is worrisome, as trade wars and promised tariffs could lead to disaster for many businesses. But that doesn't mean you should necessarily get out of the market. On the contrary -- this can be an optimal time to score some deals and investments you can hang on to for the long haul.If you've got $5,000 you can afford to invest in the stock market today, three stocks you'll want to consid ...

The Nasdaq Composite index is home to almost every stock listed on the Nasdaq exchange, so it's typically a good proxy for the performance of the broader technology industry. As of this writing, it's down by 14% from its recent all-time high, which places it firmly in correction territory.Investors are trying to digest rising uncertainty relating to global trade policies, which could affect economic growth and corporate earnings. But throughout history, the U.S. stock market has always climbed to new highs ...

Core Viewpoint - The U.S. stock market has faced challenges, with the S&P 500 down 8% and the Nasdaq Composite down 14%, presenting a buying opportunity, particularly for technology stocks listed on Nasdaq [1] Group 1: Shopify - Shopify has a 42% upside potential based on Wall Street's median target price [3] - The company provides commerce software and services, ranking as a leader in digital commerce platforms for mid-market businesses [3][4] - Shopify's merchants account for over 12% of U.S. retail e-commerce sales and 6% in Western Europe, making it the second-largest e-commerce company in these regions [4] - The B2B e-commerce market, where Shopify has been recognized as a leader, is three times larger than retail e-commerce and growing nearly twice as fast [5] - In Q4, Shopify's revenue increased by 31% to $2.8 billion, with non-GAAP earnings rising 29% to $0.44 per diluted share [6] - The median stock price target for Shopify is $135, indicating a 42% upside from the current price of $95, with expected earnings growth of 24% in 2025 [7] Group 2: MongoDB - MongoDB has a 73% upside potential based on Wall Street's median target price [8] - The company is recognized as a leader in cloud database management systems, with strengths in transaction processing and analytical capabilities [9] - MongoDB's customer base grew by 14% to 54,500, with revenue rising 20% to $548 million in Q4 of fiscal 2025 [10] - The median target price for MongoDB is $300, suggesting a 73% upside from the current price of $173 [11] - Despite disappointing guidance predicting a 30% earnings decline in fiscal 2026, MongoDB's current valuation of 65 times forward earnings is the lowest in its history [12]

Macro uncertainty has delayed the timeline for an IPO comeback, but there remains substantial pent-up supply for equity issuance.That’s according to BofA Securities analyst Craig Siegenthaler, who maintained all of his ratings and continues to look for a reopening in the second half of 2025. This will restart Nasdaq, Inc‘s NDAQ strategic flywheel across listings, trading, and corporate services, he says.Also Read: Nasdaq Plans 24-Hour Trading To Tap Global Investor DemandSiegenthaler continued to forecast t ...

Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate Development IR@biomeafusion.com Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offe ...

Português Deutsch Italiano Español FX Empire Logo English check-icon Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you sho ...